menu search

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fid...

April 16, 2023, 9:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm


Search within

Pages Search Results: